acs是否应该早期介入治疗.pptxVIP

会计学;Pathophysiology of Acute Coronary Syndrome;ACS is an Important Manifestation of Atherothrombosis1;;Relation of TIMI risk score and MACE rate;Hot topic in ACS;;Optimal Strategy for UA/NSTEMI;FRICS-II: high risk get more;TIMI-18: high risk get more;RITA-3: 13 yrs outcome;RITA-3: 5yrs outcome;第12页/共60页;;第14页/共60页;In 2005,It seems we found answer;ESC Guideline 2005;第17页/共60页;Is the problem settled?;ICTUS Designed;第20页/共60页;第21页/共60页;第22页/共60页;第23页/共60页;;第25页/共60页;4 yrs ICTUS Lancet 2007;369:827-835;;ICTUS’s criticism ;Even put ICTUS into pool, Inv Cons;Inv vs Cons/All cause death ;第31页/共60页;;2007 ESC Guideline;Monocyte;ISAR-COOL Trial;ISAR-COOL Antithrombotic Regimen;第37页/共60页;ISAR-COOL;第39页/共60页;第40页/共60页;;What is the optimal time for PCI?;;Methods for Optimal trial;Results of Optimal trial;Conclusion from Optimal trial;What’s the difference between ISAR-Cool Optimal?;Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial ;Background;Study Objective;Study Population;Adjusted Estimates of 30-day Death/MI Rates (with 95% CI);Landmark Analysis: Adjusted OR of 30-day Death/MI (with 95% CI);Adjusted Estimates of In-hospital Transfusion Rates (with 95% CI);Study Limitations;Conclusions from Synergy- 1;Conclusions from Synergy- 2;Conclusion Prospective;